Argenx (ARGX, Financial) has received a positive recommendation from the Committee for Medicinal Products for Human Use, a key body of the European Medicines Agency, for its Vyvgart 1000mg. This development signifies a step closer to gaining European Commission approval for the drug's use.
Vyvgart is designed as a subcutaneous injection intended to serve as a monotherapy in the treatment of adult patients suffering from progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP). Importantly, it targets those who have previously been treated with corticosteroids or immunoglobulins.
This endorsement marks a significant advancement for Argenx (ARGX, Financial) in expanding its treatment options for CIDP, potentially offering a new path for patients battling this challenging condition in Europe.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for argenx SE (ARGX, Financial) is $737.80 with a high estimate of $1,100.00 and a low estimate of $416.00. The average target implies an upside of 20.01% from the current price of $614.76. More detailed estimate data can be found on the argenx SE (ARGX) Forecast page.
Based on the consensus recommendation from 25 brokerage firms, argenx SE's (ARGX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for argenx SE (ARGX, Financial) in one year is $1912.06, suggesting a upside of 211.03% from the current price of $614.76. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the argenx SE (ARGX) Summary page.
